The future of heart replacement therapy: four frontiers of transformation

Heart transplantation has always lived in paradox: it is both the most advanced form of organ replacement and one of the most biologically constrained. For over half a century, we have relied on a miracle of logistics—hearts must be found, matched, and implanted within hours. Immunological barriers must be crossed, complications managed, survival extended. And yet, despite all obstacles, the human heart has been replaced successfully in thousands of patients, giving new life where none seemed possible. But now, the future asks for more than success—it asks for evolution. Around us, four converging revolutions are reshaping what heart replacement therapy could become. Technologies that defy ischaemic time. Machines that mimic or even surpass biology. Bioengineered organs born in labs, not in donors. And intelligent systems that personalize decisions beyond human capacity. This future is not linear. It does not replace one model with another. It is a synthesis: a reimagining of time, material, biology, and cognition. What follows is not a prediction—it is a possibility. And it begins with the most foundational change of all (Figure 1): Once a relentless ticking clock, time has long defined the limitations of heart transplantation. But that era is ending. Advances in preservation now allow us not only to transport hearts across continents but to treat and improve them while they wait. With cold-controlled static systems (e.g. SherpaPak™), hypothermic oxygenated perfusion (HOPE), and normothermic ex vivo perfusion (e.g. OCS™), ischaemia is no longer fate—it’s a manageable risk.1 What’s more, the preservation window has evolved into a therapeutic platform. During ex situ perfusion, donor hearts can be modulated biologically: ischaemia-reperfusion damage can be mitigated, inflammatory cascades attenuated, and even genetic properties altered. Early studies have demonstrated the feasibility of viral inactivation (e.g. HCV), immunomodulatory gene therapy (IL-10), and antigen conversion (ABO) in perfused organs.1,2 Targeted approaches may soon reduce immunogenicity or enhance resilience, allowing broader and safer use of the so-called marginal hearts.1 These advances are not incremental—they are transformative. They redefine what a ‘transplantable’ heart is. And they allow for what once seemed impossible: global organ exchange with safe, extended preservation. The heart no longer races against time. In the near future, it may be the one that sets the pace. The four pillars of the future heart. Heart replacement therapy is undergoing a profound transformation across four converging domains: (1) Time—dynamic preservation platforms extend ischaemic windows and enable therapeutic modulation of donor hearts; (2) Mechanics—next-generation artificial and hybrid hearts integrate biocompatibility, adaptive circulation, and smart sensor technologies; (3) Biology—bioengineered organs via xenotransplantation, decellularization, and 3D printing may offer scalable alternatives to donor shortages; and (4) Intelligence—AI-driven risk prediction, personalization, and nanoparticle-based therapies redefine decision-making and tolerability. These pillars are not replacements of one another, but components of a new integrative paradigm for cardiac replacement—one that reimagines biology, material, time, and cognition While biological hearts remain the gold standard, mechanical alternatives are evolving beyond their role as mere stopgaps. The total artificial heart (TAH) is no longer a futuristic curiosity—it is becoming a viable platform for long-term support and destination therapy. Devices are shrinking, becoming smarter, and integrating seamlessly into patients’ daily lives. Cable-free energy transfer, sensor-guided self-regulation, and remote monitoring are transforming these systems from passive pumps into responsive, intelligent companions.3 The next generation of mechanical hearts won’t just mimic cardiac output—they will adapt in real time. Embedded algorithms can respond to physiologic stress, adjust flow, and even predict complications before they manifest clinically. As bio-compatible surfaces improve, hybrid solutions combining mechanical strength with biologically active interfaces may reduce thrombosis and infection risk.4 Beyond bridging to transplant, mechanical hearts are increasingly used in patients who may never receive a donor organ. In an ageing population with growing contraindications to immunosuppression, this may define a new frontier. Tomorrow’s mechanical heart is a design choice—no longer a compromise. And with each iteration, we move closer to a device that doesn’t just support circulation but participates in the patient’s life with autonomy, safety, and dignity. If mechanics offer precision, biology offers promise. The idea of growing or customizing human-compatible hearts is no longer confined to speculative science. Efforts in xenotransplantation, decellularization, recellularization, and 3D bioprinting are converging towards one goal: replacing the need to wait for a suitable donor by creating one.5 Genetically engineered pig hearts have already been transplanted into humans in pioneering trials. While challenges remain—early graft failure, infection risk, and ethical complexity—these cases demonstrate technical feasibility. Further refining immunogenic profiles through CRISPR-based edits and pathogen elimination may push xenotransplantation from heroic exception to scalable solution.5,6 Parallel efforts are exploring biofabrication. Decellularized human or animal scaffolds seeded with patient-derived cells, or fully printed constructs using hydrogel matrices and vascular bioinks, are inching closer to functional prototypes. These constructs lack native contractility—but with progress in materials and biophysics, it’s no longer if, but when.5,7 Biological design is the most ambitious pillar in the future of heart replacement—less mature than others, but arguably the most transformative. In time, we may shift from ‘matching’ organs to ‘designing’ them—tailored for the recipient’s anatomy, immunology, and destiny. Heart replacement has long relied on urgency, size, and geography. But a new paradigm is emerging—one where data, not distance, drives decisions. Artificial intelligence (AI) is poised to revolutionize every step of the transplant process: from donor selection to recipient matching, from risk prediction to therapy personalization. Machine learning algorithms already assist in assessing donor heart quality beyond traditional metrics.5,8 By integrating imaging, biomarkers, and molecular profiles, AI can better predict graft resilience, even before procurement. Matching tools now incorporate not only weight and blood type, but dynamic estimations of immunological compatibility and post-transplant prognosis.8,9 The next frontier is true individualization. Systems like the iBox or I-Score aim to forecast long-term outcomes based on multi-omic, clinical, and behavioural data.5,9 Digital twins may simulate how a heart performs in a specific patient. This moves us from ‘suitable’ to ‘optimal’.5 Emerging technologies also hint at precision drug delivery: nanoparticles targeting immunosuppressants directly to the graft, reducing systemic toxicity.10 While tolerance induction remains elusive, such approaches may reduce the burden of lifelong immunosuppression. In this data-driven future, the heart transplant becomes not just a procedure—but a calculated, continuously adapting therapy. And AI does not replace physicians—it sharpens their lens on what truly matters: outcomes tailored to the individual. The heart has always symbolized life. In the future of heart replacement, it becomes more: a platform for innovation, integration, and imagination. We no longer ask only how to replace a failing heart—but what else can be transformed along the way: time, matter, identity, and decision. Each of the four pillars—preservation, mechanics, biological creation, and intelligent systems—stands alone. But together, they form the architecture of a new era. One where boundaries dissolve and possibilities multiply. This is not science fiction. It is science becoming future. The heart—still fragile, still human—remains at the centre. But around it, we build a system that thinks and adapts. The corresponding author, Andreas Zuckermann declares the following potential conflicts of interest: Speaker Honoraria/Advisory Roles: Paragonix Technologies, Therakos (Mallinckrodt), Takeda, Sanofi Study Involvement: Local Principal Investigator: XVIVO NHIP2019 study, Cytotect NIS021 (Biotest) European Principal Investigator: GUARDIAN registry (Paragonix) Institutional Study Support (non-personal): Biotest NIS021 Advisory Board Participation: Sanofi, Therakos Independent Adjudicator for PGD: Xvivo Several of the above-mentioned relationships relate to immunosuppressive or organ preservation strategies used in the field of transplantation and are declared in full transparency. A.F. has nothing to declare. A.A.-Z. has nothing to declare.